Skip to content
+49 40 3009799 0 order@oncoscience.de
EnglishEnglish
  • DeutschDeutsch
Oncoscience
  • COMPANY
  • ONCOLOGY
  • PRODUCT
  • RESEARCHExpand
    • CLINICAL TRIALS
    • PUBLICATIONS
  • FAQ
  • NEWS
+49 40 3009799 0 
EnglishEnglish
  • DeutschDeutsch
Oncoscience
Allgemein | NEWS

Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab.

ByOncoscience 6. November 202017. July 2025

Read More Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab.Continue

Allgemein

Children with diffuse intrinsic pons glioma (DIPG) benefit from nimotuzumab

ByOncoscience 25. March 201917. July 2025

Read More Children with diffuse intrinsic pons glioma (DIPG) benefit from nimotuzumabContinue

Oncoscience GmbH
Osterbrooksweg 59
22869 Schenefeld
Germany

 

Phone: +49-40 300 9799-0
Fax: +49-40 300 9799-20
Email: order@oncoscience.de

part of

Legal Notice

© 2025 Oncoscience

Scroll to top
  • COMPANY
  • ONCOLOGY
  • PRODUCT
  • RESEARCH
    • CLINICAL TRIALS
    • PUBLICATIONS
  • FAQ
  • NEWS
Search
Diese Website benutzt Cookies. Wenn du die Website weiter nutzt, gehen wir von deinem Einverständnis aus.OKDatenschutzerklärung